解晓静;高铭佑;张礼萌;赵阔;赵宁;刘贤明

• 1:天津市肿瘤医院空港医院肿瘤内科，天津 300060

摘要(Abstract)：

关键词(KeyWords)： 头颈部鳞癌;尼妥珠单抗;白蛋白结合型紫杉醇

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 解晓静;高铭佑;张礼萌;赵阔;赵宁;刘贤明

DOI: 10.13267/j.cnki.syzlzz.2022.029

参考文献(References)：

• [1] 王佳峰,葛明华.头颈部黏膜鳞状细胞癌全球诊治新进展[J].实用肿瘤杂志, 2020, 35(1):16-18.
  [2] Babu KG, Viswanath L, Reddy BK, et al. An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage Ⅲ or Ⅳa) squamous cell carcinoma of head and neck (SCCHN):Four-year survival results from a phase Ⅱb study[J]. J Clin Oncol, 2010, 28(15_suppl):5530.
  [3] 吴事海,韩灵,徐纲,等.尼妥珠单抗联合放化疗治疗局部晚期头颈部恶性肿瘤的临床效果观察[J].临床合理用药杂志, 2019, 12(5):17-18.
  [4] 应学明,陈俊,汤声波.顺铂同步化疗联合尼妥珠单抗用于局部晚期头颈部鳞癌的近期疗效观察[J].中国药房, 2012, 23(48):4566-4569.
  [5] 王兴,孟箭,邵翠玲,等.尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶化疗治疗晚期及转移性头颈部鳞癌的临床疗效评价[J].中华转移性肿瘤杂志, 2018, 1(3):39-43.
  [6] 黄佳欢,雷蕾,王晓稼.白蛋白结合型紫杉醇治疗晚期乳腺癌的研究进展[J].实用肿瘤杂志, 2021, 36(6):496-501.
  [7] Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxeland nab-paclitaxel[J]. Clin Cancer Res, 2008, 14(13):4200-4205.
  [8] Ley J, Wildes TM, Daly K, et al. Clinical benefit of nanoparticle albuminbound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel[J]. Med Oncol, 2017, 34(2):28.